Edgewise Therapeutics, Inc. Cash Flow Statement
EWTX / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Edgewise Therapeutics, Inc. used $144M in operating cash flow and negative free cash flow of $144M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$167.8M | -$133.8M | -$100.2M | -$67.6M | -$42.8M | -$17.1M |
| Depreciation & Amortization | $2.1M | $2.1M | $1.6M | $368.0K | $272.0K | $185.0K |
| Operating Cash Flow | -$143.8M | -$109.0M | -$91.9M | -$52.6M | -$33.5M | -$14.6M |
| Capital Expenditures | $256.0K | $1.3M | $5.7M | $5.5M | $668.0K | $203.0K |
| Free Cash Flow | -$144.1M | -$110.3M | -$97.7M | -$58.2M | -$34.2M | -$14.8M |